Shionogi & Co., Ltd. has announced that in the final stage of clinical trials, it has been confirmed that the oral medicine for the new corona, which is being developed so that people without the risk of aggravation can take it, is effective in improving symptoms such as fever.
This drug is under ongoing deliberation at the Ministry of Health, Labor and Welfare council regarding approval, but the company says that it has obtained good results and will submit the data again.
On the 28th, Shionogi & Co., Ltd. announced the results of the final-stage clinical trial of the new corona oral drug "Zokoba", which is under development.
According to it, the clinical trial will target more than 1,800 mild to moderate corona patients from 12 to 60 years old, including those who are not at risk of becoming severe and those who have been vaccinated. It lasted until mid-March.
Among them, the group was divided into a group that took "Zokoba" once a day for 5 days and a group that took a placebo. In the group who took ", all five symptoms of cough, sore throat, runny nose / stuffy nose, malaise, fever / fever disappeared around 7 days, and it was shortened by about 24 hours.
In addition, on the fourth day of administration, the amount of virus was greatly reduced, and there were no serious side effects.
Regarding this drug, Shionogi & Co. applied for approval to the Ministry of Health, Labor and Welfare using the emergency approval system as the first oral drug that can be taken by people without the risk of aggravation. The deliberation was continued as there was insufficient data to estimate the
The company says that the results of the clinical trial have yielded good results and will be submitted to the Ministry of Health, Labor and Welfare again.